Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

China Implements New Drug Innovation And Production Project

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Science and Technology has officially started implementing the new drug innovation and production project to become a pharmaceutical powerhouse (PharmAsia News, Sept. 8, 2008). The country's program with the highest investment, has allocated RMB 5.3 billion ($775 million) for a total of 970 research topics. The first batch of 121 topics with funding of RMB 1 billion has commenced. The second batch of 849 topics which will use the remaining funds has been identified and are ready to go. Sang Guo-wei, chief technology director for the program, stated that chemical drugs will be the emphasis, biopharmaceutical products the highlight and TCM the unique feature. (Click here for more - Chinese language)

Table

View full table

Tags:
Latest Headlines

China Biotech Podcast: AACR, BIOSECURE European Perspectives

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

See All
UsernamePublicRestriction

Register

SC071579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By